New Delhi January 9, 2014: Ranbaxy Laboratories’ Canadian subsidiary Ranbaxy Pharmaceuticals Canada Inc has received approval to manufacture and sell Donepezil Hydrochloride 5 mg and 10 mg. The drug is used to treat dementia in patients suffering from Alzheimer’s, the company said in a statement on Wednesday.
According to the company, the total market size for the drug in Canada was 153.9 million Canadian dollars in November 2013 and is growing at about 38 per cent.
Paul Drake, President, Ranbaxy Pharmaceuticals Canada, said the medicines will be manufactured at Ohm Laboratories located in New Jersey, US.
Ranbaxy came in the firing line for regulatory issues last year. In May last year, the company made a $500-million legal settlement in the US after pleading guilty to drug safety violations. Later, in September the US Food and Drugs Administration (FDA) also issued an import alert on Ranbaxy’s third Indian plant at Mohali.
Further, in December 2012, Ranbaxy’s Ohm Laboratories had also come under the US FDA lens for failing to comply with the current good manufacturing practices. It received a clean chit only in October 2013. Ohm Laboratories is the only manufacturing facility catering to the US market since all three Indian plants — Mohali, Paonta Sahib and Dewas — are barred from manufacturing drugs for the US. Business Standard
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…